[G09-01] Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

Last updated 29.10.2013

Project no.:
G09-01

Commission:
Commission awarded on 17.12.2009 by the Federal Joint Committee (G-BA).

Report type:
Report

Status:
Commission completed

Department/Division:
Health Economics

Topic:
Mental and emotional wellbeing

30.10.2013

IQWiG: First health economic evaluation completed

Report on health economic evaluation of antidepressants provides very helpful results / Discussion is still pending about the future role of health economic evaluations in the hea...

Press release

Executive summary of the final report: Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

EN, PDF, 292 kB, PDF

published on Oct 30, 2013
Final report: Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

DE, PDF, 5 MB, PDF

published on Oct 30, 2013
Documentation and evaluation of comments on the preliminary report: Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

DE, PDF, 2 MB, PDF

published on Oct 30, 2013
Executive summary of the preliminary report: Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

DE, PDF, 318 kB, PDF

published on Nov 19, 2012
Preliminary report: Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

DE, PDF, 4 MB, PDF

published on Nov 19, 2012
Annex 1 to the preliminary report: Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

PDF, 634 kB, PDF

published on Nov 19, 2012
Annex 2 to the preliminary report: Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

ZIP, 27 kB

published on Nov 19, 2012
Report plan version 1.0: Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

DE, PDF, 431 kB, PDF

published on May 17, 2011
Documentation and appraisal of comments on the preliminary report plan: Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

DE, PDF, 4 MB, PDF

published on May 17, 2011
Preliminary report plan: Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

DE, PDF, 370 kB, PDF

published on Oct 26, 2010

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form